Histological/ Immunohistological and Molecularpathological Types of Epulides and Central Giant Cell Lesions of the Jaws
Retrospective Clinico-pathological Examinations on Different Histological/ Immunohistological and Molecularpathological Types of Epulides and Central Giant Cell Lesions of the Jaws
Study Overview
Status
Conditions
Detailed Description
Different histopathological differential diagnoses can underlay the clinical presentation of an epulis. Often the immunophenotype of these lesions is of particular importance. This also holds for the the central giant cell lesion.
This study will evaluate the patient collective of the Division of Oral Surgery and Orthodontics, Department of Dental Medicine and Oral Health and of the Division of Cranio-Maxillofacial Surgery at the Medical University Graz concerning the frequency of epulis/giant cell lesion or underlying differential diagnoses and immunophenotypes as well as the resulting treatment methods and their success and compare these with international results.
This is a retrospective study using electronic patient records, written records, operative reports of the Division of Oral Surgery and Orthodontics, Department of Dental Medicine and Oral Health and of the Division of Cranio-Maxillofacial Surgery at the Medical University Graz in the period from 1986 to March 2018. It is intended to gather the data within 12 months and analyze statistically subsequently.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Graz, Austria, 8036
- Medical University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- existence of a medical history and a histopathological finding of the surgical specimen
- patients treated in the outpatient clinic for diseases of oral mucosa of the Division of Oral Surgery and Orthodontics, Department of Dental Medicine and Oral Health and of the Division of Cranio-Maxillofacial Surgery at the Medical University Graz between 1986 and March 2018
Exclusion Criteria:
- absence of a medical history or a histopathological finding.
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Frequency of histological pathological differential diagnoses.
Time Frame: time period of evaluation from 1986 to March 2018
|
time period of evaluation from 1986 to March 2018
|
|
Frequency of immunohistochemical pathological differential diagnoses.
Time Frame: time period: from 1986 to March 2018
|
time period: from 1986 to March 2018
|
|
Frequency of molecular pathological differential diagnoses.
Time Frame: time period from 1986 to March 2018
|
time period from 1986 to March 2018
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Frequency of recurrences
Time Frame: time period from 1986 to March 2018
|
depending on differential diagnoses and therapy
|
time period from 1986 to March 2018
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- GCG
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.